Prevention and treatment of intertrigo in large skin folds of adults: A systematic review

BMC Nursing

Volumn 9, Issue , 2010, Pages

  Mistiaen, Patriek ^a   van Halm Walters, Meike ^b  

^a NETHERLANDS INSTITUTE FOR HEALTH SERVICES RESEARCH   (Netherlands)

^b LEVV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77954400120     PISSN: None     EISSN: 14726955     Source Type: Journal    
DOI: 10.1186/1472-6955-9-12     Document Type: Article

References (86)

1. van Duijn HJ. Intertrigo. Minor ailments in primary care - An evidence based approach 2005, 63-65. Maarssen: Elsevier Gezondheidszorg, Eekhof J, Knuistingh Neven A, Verheij T.
2. van Duijn HJ, Mulder J. Kleine kwalen in de huisartsgeneeskunde: smetten onder de borsten. Ned Tijdschr Geneeskd JID - 0400770 1988, 132:1842-1843.
3. Janniger CK, Schwartz RA, Szepietowski JC, Reich A. Intertrigo and common secondary skin infections. Am Fam Physician 2005, 72:833-838.
4. Arndt K, Bowers K. Manual of dermatologic therapeutics 2002, Philadelphia: Lippincott Williams & Wilkins, 6.
5. Itin P. [Intertrigo--a therapeutic problem circle]. Ther Umsch 1989, 46:98-101.
6. Halfens RJ, Meijers J, Neyens JCL, Offermans MPW. Rapportage resultaten Landelijke Prevalentiemeting Zorgproblemen 2008, Maastricht: Maastricht University.
7. Halfens R, Wansink S. Landelijke prevalentiemeting decubitus en andere zorgproblemen: resultaten zevende jaarlijkse meting 2004 2004, Maastricht: Universiteit Maastricht.
8. Halfens R, Janssen M, Meijers J. Landelijke prevalentiemeting zorgproblemen: rapportage resultaten 2006 2006, Maastricht: Universiteit Maastricht.
9. Mistiaen P, Wagner C, Bours G, Halfens R. Prevalentiemeting van smetten in Nederlandse intramurale zorginstellingen 2003, Utrecht: NIVEL.
10. Mistiaen P, Poortvliet M. Smetten. Landelijke prevalentiemeting zorgproblemen: Rapportage resultaten 2005 2005, 77-86. Maastricht: Universiteit Maastricht, Halfens R, Janssen M, Meijers J, Mistiaen P.
11. Halfens R, Meijers J, Neyens J, Offermans M. Landelijke prevalentiemeting zorgproblemen: rapportage resultaten 2007 2007, Maastricht: Universiteit Maastricht.
12. McMahon R. The prevalence of skin problems beneath the breasts of in-patients. Nurs Times 1991, 87:48-51.
13. , . LEVV, NVDVV, NIVEL Smetten (intertrigo): preventie en behandeling. landelijke richtlijn verpleging en verzorging 2004, Utrecht: LEVV, LEVV, NVDVV, NIVEL.
14. Mistiaen P, Poot E, Hickox S, Jochems C, Wagner C. Preventing and treating intertrigo in the large skin folds of adults: a literature overview. Dermatol Nurs 2004, 16:43-57.
15. National Institute for Health and Clinical Excellence The guidelines manual 2009, London: National Institute for Health and Clinical Excellence, National Institute for Health and Clinical Excellence.
16. Chapman M, Brown J. Tacrolimus 0.1% ointment for intertrigo. J Am Acad Dermatol 2005, 52:61.
17. Chapman MS, Brown JM, Linowski GJ. 0.1% tacrolimus ointment for the treatment of intertrigo. Arch Dermatol 2005, 141:787. 10.1001/archderm.141.6.787-a, 15967933.
18. Spector JA, Singh SP, Karp NS. Outcomes after breast reduction - Does size really matter?. Annals of Plastic Surgery 2008, 60:505-509. 10.1097/SAP.0b013e31816f76b5, 18434823.
19. Spector JA, Karp NS. Reduction mammaplasty: A improvement at any size. Plastic and Reconstructive Surgery 2007, 120:845-850. 10.1097/01.prs.0000277660.49802.76, 17805110.
20. Cullen SI, Rex IH, Thorne EG. A comparison of a new antifungal agent, 1 percent econazole nitrate (Spectazole(registered trademark)) cream versus 1 percent clotrimazole cream in the treatment of intertriginous candidosis. Curr Ther Res Clin Exp 1984, 35:606-609.
21. Hedley K, Tooley P, Williams H. Problems with clinical trials in general practice--a double-blind comparison of cream containing miconazole and hydrocortisone with hydrocortisone alone in the treatment of intertrigo. Br J Clin Pract 1990, 44:131-135.
22. Miura Y, Onuki M, Takahashi S, Seiji M, Akihiko SATO, Kagawa S, et al. A Double-Blind Study on Utility of Econazole Cream in Dermatomycosis. Rinsho Hyoka (Clinical Evaluation) 1979, 7:83-108.
23. Nozickova M, Koudelkova V, Kulikova Z, Malina L, Urbanowski S, Silny W. A comparison of the efficacy of oral fluconazole, 150 mg/week versus 50 mg/day, in the treatment of tinea corporis, tinea cruris, tinea pedis, and cutaneous candidosis. Int J Dermatol 1998, 37:703-705. 10.1046/j.1365-4362.1998.00541.x, 9762826.
24. National Institute for Health and Clinical Excellence The guidelines manual 2009, London: National Institute for Health and Clinical Excellence, National Institute for Health and Clinical Excellence.
25. Bergson VS, Franklin WH. Temetex in the treatment of steroid-responsive dermatoses. J Int Med Res 1977, 5:33-36.
26. Schindera I. Current intertrigo therapy - Treatment results with Hamamelis virginiana. Forsch Komplementarmed Klass Naturheilkd 1999, 6:31-32.
27. Grigoriu A, Grigoriu D. Superficial mycoses: Ketoconazole treatment. Mykosen 1982, 25:258-262.
28. Puiatti P, Cervetti O, Forte M, Zina G. Ketoconazole treatment in superficial mycoses. Drugs Exp Clin Res 1986, 12:405-407.
29. Almeyda JJ, Feiwel M, Thorne N, Vickers CF. "Timodine" cream in the treatment of flexural dermatoses and napkin rash. Practitioner 1974, 213:864-867.
30. Alteras I, Cojocaru I. [Antifungal activity of pimaricin]. Mycoses 1969, 12:139-149.
31. Amerighi F, Spagnoli U. Experiments in treatment using ketoconazole in new 2% dermatological powder. G Ital Dermatol Venereol 1984, 119:XIII-XXVI.
32. Anonymous Estudo da associaçäo de fluprednilideno, sulfato de gentamins e 5-cloro-8-hidroxiquinolina no tratamento de lesoes infectadas/Association of flupredniliden, gentamicin sulphate and 5-chloro-8-hydroxiquinolin in the treatment of infectal lesions. Folha Med 1989, 99:45-48. Anonymous.
33. Aussems J. [Clinical study of a bufexamac-nystatin-neomycin combination in dermatology]. Brux Med 1972, 52:797-799.
34. Baran R, Beurey J, Civatte J. Multicentric clinical trial of a new combination of a broad spectrum antimycotic in a dermocorticoid. Sem Hop 1979, 55:269-272.
35. Durand JR. Clinical trial of a mixture of neomycin, bacitracin, natamycin and dexamethasone. MEDITERR MED 1975, 3:71-74.
36. Engel MF. Amphotericin B lotion in monilial intertrigo: a double-blind paired comparison study. Arch Dermatol 1965, 92:687. 10.1001/archderm.1965.01600180079014, 5321198.
37. Franks AG, Taschdjian CL, Thorpe GA. Effect of candicidin in intertriginous and paronychial moniliasis. J Invest Dermatol 1954, 23:75-76.
38. Gip L. [Clinical testing of Fungiplex ointment on a geriatric material with intertriginous Candida mycosis]. Dermatol Wochenschr 1966, 152:482-484.
39. Gisslen H, Hersle K, Mobacken H. Topical treatment of cutaneous candidiasis with 5 fluorocytosine compared with nystatin. Dermatologica 1974, 148:362-365. 10.1159/000251929, 4607694.
40. Grupper C. [Treatment of some dermatoses caused by yeast fungi (moniliasis of the pyodermitis vegetans type, intertrigo, onyxis and perionyxis) with the new fungicide: mycostatin or nystatin.]. Bull Soc Fr Dermatol Syphiligr 1954, 61:495-498.
41. Guha DK, Behera FC, Patro SC. Topical therapy with Jadit (Buclosamide) in dermatomycoses. INDIAN J DERMATOL 1974, 19:61-63.
42. Guilhou E. Miconazole plus hydrocortisone in dermatology. MEDITERR MED 1979, 7:22-23.
43. Hempel M. [Clinical experiences in the local treatment of dermatomycoses with Econazole lotion]. Mykosen 1975, 18:213-219.
44. Masse R, Nedelec J, Dorval JC. Therapeutic trial of an econazole-triamcinolone combination. OUEST MED 1980, 33:157-159.
45. Otcenasek M, Pec J, Moravcik P. [Naftifin--laboratory and clinical experience with a new antimycotic from the allylamine group]. Cas Lek Cesk 1993, 132:406-409.
46. Radovic-Kovacevic V, Ratkovic R, Milenkovic A. [Obytin in the treatment of superficial skin mycoses]. Med Pregl 1990, 43:329-331.
47. Reiffers J. [Clinical report of triclosan, a new topical with antifungicidal and antimicrobial activity (CGP 433--Logamel) (author's transl)]. Schweiz Rundsch Med Prax 1981, 70:1050-1053.
48. Rosanove R. "Kenacomb" cream in the treatment of intertrigo. Med J Aust 1967, 2:676-678.
49. Scherwitz C. [Clinical testing of Econazole skin lotion and cream in dermatomycoses]. Z Hautkr 1977, 52:117-125.
50. Schmidt P. Therapeutic experience with CG 3225 polyvalent ointment (Topsym). CLIN TRIALS J 1975, 12:53-59.
51. Schwarz KJ, Much T, Konzelmann M. [Evaluation of econazol in 594 cases of skin mycosis (author's transl)]. Dtsch Med Wochenschr 1975, 100:1497-1500. 10.1055/s-0028-1106606, 124247.
52. Siboulet A. [Econazole spray-powder in dermo-venereology (authors transl)]. Schweiz Rundsch Med Prax 1976, 65:977-981.
53. Somorin AO. Clinical evaluation of tioconazole in dermatophyte infections. Curr Ther Res Clin Exp 1985, 37:1058-1061.
54. Szepes E, Schneider I. Ciclopiroxolamine in the treatment of dermatomycoses. Mykosen 1986, 29:382-386.
55. Taube KM, Duhr M, Koepke M, Haustein UF. Treatment of fungal infections of the skin with tioconazole. Z DERMATOL 1995, 181:125-128.
56. Thomas J, Saint-Andre P, Cornudet B. [Local use of thiabendazole in the treatment of certain superficial mycoses]. Bull Soc Pathol Exot Filiales 1971, 64:316-322.
57. Varma R, Cantrell W, Werlinger K, Elewski BE. A new gel formulation of miconazole nitrate 2% for the treatment of chronic intertrigo. Cosmetic dermatology 2007, 20:43-44.
58. Vogt G. Intertriginous mycosis and its treatment. ARZTL KOSMETOL 1985, 15:178-183.
59. Wanic A. [Therapeutic trials of various skin diseases using chinoline and chinaldine derivatives]. Z Haut Geschlechtskr 1967, 42:27-32.
60. Wurster J. Treatment of intertriginous dermatosis and diaper dermatitis with a combination of econazole and zinc oxide. ARS MED 1993, 83:792-795.
61. Becker SW. An eight investigator analysis of a newly formulated low dosage corticosteroid. Cutis 1973, 12:283-285.
62. Gatti JC, Cardama JE, Balina LM. [Our observations with the topical use of Fluocinolone acetonide]. Dia Med 1963, 35:1509.
63. Hofer P. Treatment of skin diseases with an antiinfective and antiinflammatory gel (Exosterol) containing phenylmercuric borate and dexamethasone pivalate. Praxis 1974, 63:1550-1553.
64. Marton K, Traore N. Clinical observations on the use of ftorocort ointment in tropical areas. THER HUNG 1977, 25:29-31.
65. Vallette P, Bonerandi, Sayag J. [Stapolidex in dermatology]. Bull Soc Fr Dermatol Syphiligr 1968, 75:490-494.
66. Venier A, Carnevali P, Alessandrini A, Urbani S. Controlled clinical trial of a topical formulation of fluocortolone (as privalate and caproate esters) plus chlorquinaldol. CLIN EUR 1982, 21:932-939.
67. Bonnefoy M, Doss N, Nouira R, Boge T. Comparative study of Cicalfate Lotion(registered trademark) versus eosine for large skin folds intertrigo treatment. Nouv Dermatol 2008, 27:257.
68. McMahon R. An evaluation of topical nursing interventions in the treatment of submammary lesions. Journal of Wound Care 1994, 3:365-366.
69. Atterhem H, Holmner S, Janson PE. Reduction mammaplasty: symptoms, complications, and late results. A retrospective study on 242 patients. Scand J Plast Reconstr Surg Hand Surg 1998, 32:281-286. 10.1080/02844319850158615, 9785431.
70. Brown AP, Hill C, Khan K. Outcome of reduction mammaplasty--a patients' perspective. Br J Plast Surg 2000, 53:584-587. 10.1054/bjps.2000.3380, 11000075.
71. Davis GM, Ringler SL, Short K, Sherrick D, Bengtson BP. Reduction mammaplasty: long-term efficacy, morbidity, and patient satisfaction. Plast Reconstr Surg 1995, 96:1106-1110. 10.1097/00006534-199510000-00015, 7568486.
72. Glatt BS, Sarwer DB, O'Hara DE, Hamori C, Bucky LP, LaRossa D. A retrospective study of changes in physical symptoms and body image after reduction mammaplasty. Plast Reconstr Surg 1999, 103:76-82. 10.1097/00006534-199901000-00013, 9915166.
73. Gonzalez F, Walton RL, Shafer B, Matory J, Borah GL. Reduction mammaplasty improves symptoms of macromastia. Plast Reconstr Surg 1993, 91:1270-1276. 10.1097/00006534-199306000-00013, 8497527.
74. Heddens CJ. Postoperative survey of reduction mammoplasty patients. Plast Surg Nurs 1993, 13:148-155.
75. Kakagia D, Harkiolakis G, Sgouras N. Symptomatic macromastia: A quality of life evaluation after reduction mammaplasty. Breast J 1998, 4:152-155.
76. Makki AS, Ghanem AA. Long-term results and patient satisfaction with reduction mammaplasty. Ann Plast Surg 1998, 41:370-377. 10.1097/00000637-199810000-00004, 9788216.
77. McMahan JD, Wolfe JA, Cromer BA, Ruberg RL. Lasting success in teenage reduction mammaplasty. Ann Plast Surg 1995, 35:227-231. 10.1097/00000637-199509000-00001, 7503513.
78. Moskovitz MJ, Muskin E, Baxt SA. Outcome study in liposuction breast reduction. Plast Reconstr Surg 2004, 114:55-60. 10.1097/01.PRS.0000127795.84891.A7, 15220568.
79. Rioja Torrejón LF, Pedreño Guerao F, Deza Rodríguez P, Benítez Gumá J, Redondo Camacho A, Haro Padilla JM. [Breast hipertrophy. Aesthetic deformity or it must be included in the national health service]. Cirugía Plástica Ibero-Latinoamericana 2006, 32:99-106.
80. Schnur PL, Schnur DP, Petty PM, Hanson TJ, Weaver AL. Reduction mammaplasty: an outcome study. Plast Reconstr Surg 1997, 100:875-883. 10.1097/00006534-199709001-00008, 9290655.
81. Shakespeare V, Cole RP. Measuring patient-based outcomes in a plastic surgery service: breast reduction surgical patients. Br J Plast Surg 1997, 50:242-248. 10.1016/S0007-1226(97)91154-1, 9215080.
82. Wagner DS, Alfonso DR. The influence of obesity and volume of resection on success in reduction mammaplasty: an outcomes study. Plast Reconstr Surg 2005, 115:1034-1038. 10.1097/01.PRS.0000154213.06888.F9, 15793442.
83. Alexander JO. Polynoxylin (Anaflex) in dermatology. Br J Dermatol 1962, 74:364-371.
84. Belaiche P. Traitement des infections cutanees par l'huile essentielle de melaleuca alternifolia.cheel. Phytotherapy 1985, 15-17.
85. Huyke C, Reuter J, Maunz H, Muller ML, Schempp M. Betulin-based ointment for the topical treatment of exudative skin conditions. Merkurstab 2008, 61:370-376.
86. Profirov D, Nikiforov N. On the antimycotic effect of the Mericleri salt. Folia Med (Plovdiv ) 1974, 16:143-145.